Correlation between Serum Heat Shock Protein 27 and Interleukin- 17 Levels and Prognosis in Patients with Acute Myocardial Infarction

Abstract

Abstract Background Heat shock protein 27 (HSP27) and interleukin-17 (IL-17) are important indicators of inflammation. Whether serum HSP27 and IL-17 levels hold predictive value on the prognosis of patients with acute myocardial infarction (AMI) remains unclear. Methods This was a prospective cohort study enrolled 140 patients in the Department of Cardiology of Fujian Provincial Hospital from December 2020 to June 2021, including 40 patients of non-AMI and 100 patients of AMI. The levels of serum HSP27, Phosphorylated HPS27 (pHSP27) and IL-17 were measured by enzyme linked immunosorbent assay. Patients with AMI were followed up. The follow-up endpoint was major adverse cardiovascular events (MACEs), including recurrent angina pectoris, re-admission heart failure, re-admission myocardial infarction, stroke, and death. And follow-up ended on December 31, 2021. Results HSP27, pHSP27 and IL-17 were higher in AMI patients than in non-AMI patients (All P < 0.05). HSP27 level was negatively correlated with troponin I level (r = -0.243, P < 0.05). And there were negative correlations between HSP27, IL-17 and Gensini scores, respectively (r(HSP27)=-0.374, P = 0.002;r(IL−17) = -0.289, P = 0.016). All 100 patients with AMI were followed up. The median follow-up was 8 months. There were 30 cases of MACEs. The area under the receiver operating characteristic curve for the predict of MACEs was higher for joint model (combining HSP27, pHSP27 and IL-17) than for HSP27, pHSP27 and IL-17 alone. Univariate COX regression analysis showed that HSP27 (HR = 0.968, P = 0.01), pHSP27 (HR = 0.972, P = 0.039) and IL-17 (HR = 0.979, P = 0.004) were protective factors for endpoint free survival. HSP27 and IL-17 were associated with MACEs after correction for confounding factors (HR(HSP27) = 0.972, P = 0.39; HR(IL−17) = 0.979, P = 0.004). Conclusion HSP27, pHSP27 and IL-17 were higher in AMI patients than in non-AMI patients. But HSP27, pHSP27 and IL-17 could reduce the occurrence of MACEs in AMI patients.